|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1667 K STREET NW, #1270 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 2558-12
|
||||||||
|
6. House ID# 310910000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Leo C. Jardot, Vice President, Government Relations |
Date | 07/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement
health care reform legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), U.S. Trade Representative (USTR), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the
Pan American Health Organization;
Childhood immunizations
Dietary supplement issues
Alzheimer's care
Pediatric Studies and Trials
Drug Safety/Clinical Trials
Health care issues
Health care reform legislation
Drug approvals
Reimbursement rates
FDA Pre-emption
Follow-on biologics
Drug importation and counterfeiting
Drug advertising
Comparative effectiveness
Physician payment disclosure
Chronic care out of pocket costs
Vaccine Program
H.R. 1427 - Access to Life-Saving Medicine Act
H.R. 1548 - The Pathway for Biosimilars Act
Legislative and regulatory issues related to hormone replacement therapies
International public health issues
International vaccine issues
H.R. 1/S350 - The American Recovery and Reinvestment Act of 2009
H.R. 579 - The Food and Drug Administration Globalization Act
S. 525/H.R. 1298 - The Pharmaceutical Market Access and Drug Safety Act of 2009
S. 301 - Physican Payments Sunshine Act of 2009
H.R. 573 - Authorized Generics
S. 501 - Fair Prescription Drug Competition Act
S. 369 - Preserve Access to Affordable Generics Act
H.R. 1706 - Protecting consumer Access to Generic Drugs Act
S.357 - Sunshine in Litigation Act of 2009
H.R. 3200 - American's Affordable Health Choices Act of 2009
S. ___ Affordable Health Choices Act
S.1213 - Patient Centered Outcomes Research Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Justice - Dept of (DOJ), Executive Office of the President (EOP), U.S. Trade Representative (USTR), State - Dept of (DOS), Natl Security Agency (NSA), Treasury - Dept of, Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bronwen |
Kaye |
|
|
|
Leo |
Jardot |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement
Importation of FDA-approved pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), U.S. Trade Representative (USTR), State - Dept of (DOS),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Taxation of International Operations of U.S. corporations generally; Homeland investment legislation; R&D tax credit; repatriation of foreign source income; deferral of U.S. taxation of foreign source income
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Vaccines
Medicare chronic disease coverage
Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003
Medicare coverage of pharmaceuticals, Medicare Part D
Chronic care out of pocket costs
Medicare Prescription Drug Benefit
Medicaid drug rebate
Medicare and Medicaid Drug Reimbursement
Medicaid Part D Non-Interference
S.301 Physician Payments Sunshine Act of 2009
S.547/H.R. 904 - Drug Rebate Equalization Act of 2009
H.R. 1725 - Voluntary State Discount Prescription Drug Plan Act of 2009
S.330/H.R. 684 - Medicare Prescription Drug Savings and Choice Act of 2009
S.266 - Medicare Prescription Drug Gap Reduction Act of 2009
H.R. ____ - House Tri-Committee Health Reform
S.____ Affordable Health Choices Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bronwen |
Kaye |
|
|
|
Leo |
Jardot |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
FDA reform proposals; Pseudoephedrine
H.R. 1259 DXM Distribution Act
Monograph System Reform Proposal
Pseudoephedrine Electronic Log Proposal
S.1383 Dextromethorphan Abuse Reduction Act of 2009
H.R. 2749 Food Safety Enhancement Act of 2009
S. 510 Food Safety Modernization Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Jardot |
|
|
|
Angela |
Riemer |
|
|
|
Julie |
Rabinowitz |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 726/H.R. 1427 - Access to Life-Saving Medicine Act, Follow-on Biologics
H.R. 1548 - The Pathway for Biosimilars Act
Biosimilars
Drug Safety
Prescription Drug Importation
Import Safety
Compounding
H.R. 759 - Food and Drug Administration Globaliation Act of 2009
S. 510 - FDA Food Safety Modernization Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |